<DOC>
	<DOCNO>NCT01128257</DOCNO>
	<brief_summary>This observational study ass compliance persistence patient , real life efficacy safety intravenously quarterly administer 3 mg ibandronate [ Bonviva/Boniva ] comparison oral alendronate generic female patient post-menopausal osteoporosis . The anticipated time assessment 12 month . The target sample size 5000-7000 patient .</brief_summary>
	<brief_title>A Study Ibandronate Bonviva/Boniva Alendronate Female Patients With Post-Menopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Adult patient , &gt; /= 55 year age Postmenopausal osteoporosis Patients opinion physician eligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>